Tartrate-resistant acid phosphatase - TRAP 5b - As a modern bone resorption marker in patients with irreversible renal failure treated with dialysis;Winianooporna kwaśna fosfataza - TRAP 5b - Jako nowoczesny wskaźnik resorpcji kości u chorych z nieodwracalna̧ niewydolnościa̧ nerek leczonych dializami

Polski Merkuriusz Lekarski

Volumn 17, Issue 98, 2004, Pages 138-141

  Nowak, Zbigniew ^a,b   Konieczna, Maria ^a   Wańkowicz, Zofia ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b Klinika Nefrologii ze Stacja Dializ   (Poland)

Author keywords

Bone turnover markers; Renal osteodystrophy; Tartrate resistant acid phosphatase

Indexed keywords

ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL PRACTICE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; OSTEOLYSIS; PARAMETER; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RENAL OSTEODYSTROPHY; STANDARD;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE RESORPTION; CALCIUM; FEMALE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PREDICTIVE VALUE OF TESTS; RENAL OSTEODYSTROPHY; SENSITIVITY AND SPECIFICITY;

EID: 4644322094     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Alatalo S.L. i wsp.: Serum tartrate-resistant acid phosphatase 5b as a marker of bone metastases in prostate cancer. J. Bone Miner. Res., 2003, 18, 536-541.
2. Cannata-Andia J. & Medical Expert Group: Clinical algorithms on renal osteodystrophy. Nephrol. Dial. Transplant., 2000, 15, suppl. 5, 39-48.
3. Capeller B. i wsp.: Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res., 2003, 23, 2, 1011-1015.
4. Chamberlain P. i wsp.: Generation and characterization of monoclonal antibodies tohuman type-5 tartrate-resistant acid phosphatase: development of a specificimmunoassay of the isoenzyme in serum. Clin. Chem., 1995, 41, 1495-1499.
5. Chu P. i wsp.: Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am. J. Kidney Dis., 2003, 41, 5, 1052-1061.
6. Coen G. i wsp.: PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am. J. Kidney Dis., 2002, 40, 2, 384-392.
7. DOQI Guidelines Kidney Disease Outcomes Quality Initiative Guideline 10 Association of level of GFR with bone disease and disorders of calcium and phosphorus metabolism. Am. J. Kidney Dis., 2002, suppl. 1, 143-168.
8. Halleen J. i wsp.: Human bone tartrate-resistantacid phosphatase: purification and development of an immunoassay. J. Bone Miner. Res., 1996, 11, 1444-1449.
9. Halleen J.M. i wsp.: Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin. Chem., 2001, 47, 597-608.
10. Halleen J.M. i wsp.: A direct two-site immunoassay for tartrate-resistant acid phosphatase. J. Bone Miner. Res., 1998, 13, 683-688.
11. Halleen J.M., i wsp.: Tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif. Tissue Int., 2002, 71, 1, 20-26.
12. Lam K.W. i wsp.: Biochemical properties of tartrate-resistantacid phosphatase in serum of adults and children. Clin. Chem., 1978, 24, 1105-1109.
13. Llach F.: Renal Osteodystrophies. In: The Kidney diseases. (ed. Saunders W.B.). Brenner E. & Rector Company. Filadelfia. 2000.
14. Looker A. i wsp.: Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteopor. Int., 2000, 11, 467-474.
15. Mehlhorn A.T. i wsp.: Immunological and histochemical determination of TRAP 5b to measure osteoclast activity under antiosteolytic treatment. Calcif. Tissue Int., 2002, 70, 266-270.
16. Nakasato Y.R. i wsp.: Clinical significance of immunoassays for type-5 tartrate-resistant acidphosphatase. Clin. Chem., 1999, 45, 2150-2154.
17. Poege U. i wsp.: Tartrate-resistant acid phosphatase 5b in bone metabolism in patients on peritoneal dialysis. J. Am. Soc. Nephrol., 2002, 13, 198-206.
18. Rico H. i wsp.: Can a determination of tartrate-resistant acid phosphatase predict postmenopausal loss of bone mass? Eur. J. Clin. Invest., 2002, 32, 274-282.
19. Urena P., Vernejoul M-C.: Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int., 1999, 55, 2141-2152.
20. Wahl H.G. i wsp.: Tartrate-resistant acid phophatase isoform 5b (TRAP): a novel serum marker of bone resorption in haemodialysis patients. Nephrol. Dial. Transplant., 2002, 17, suppl. 12, 197-204.
21. Woitge H.W. i wsp.: Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J. Bone Miner. Res., 1999, 14, 792-797.